SMO and urothelial carcinoma: As per findings of a few studies, dysregulation of SHH ligand or one of its downstream mediators, for instance, PTCH1, SMO, or GLI1, has been linked to urothelial carcinoma initiation and progression8,25,26 and in modulating cancer stem cell activities27.